An observational study in Severe Falciparum Malaria, sponsored by University of Oxford. Completed at 1 site in Bangladesh. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2015-01-22.
Sponsored by University of Oxford · Observational
acidosis, acute renal failure and acute pulmonary oedema are common, and frequently fatal, manifestations of severe P. falciparum malaria. The course of all three might be ameliorated by optimising a patient's intravenous fluid therapy. The fluid treatment of severe malaria is presently empirical, by defining cardiovascular responses to volume replacement we would provide a physiological basis for resuscitation strategies.
We will use pulse contour cardiac output monitoring (PiCCOTM) to guide the fluid resuscitation of patients admitted to intensive care with severe malaria. With data collected during the patients' admission we hope to:
In this way we hope to develop a greater understanding of the pathophysiology of haemodynamic derangement in severe malaria. By comparing the PiCCO derived data with simpler clinical parameters, we hope to determine potential fluid resuscitation strategies - relevant for a resource poor setting - whose efficacy could be confirmed in future trials.
1,299 studies on the registry are indexed under Malaria; 86 are open to participants now.
This study's planned enrollment of 80 is below the median of 600 across 218 observational studies indexed under Malaria.
Browse Malaria studies →University of Oxford is the lead sponsor of 794 studies on the registry; 117 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Severe Falciparum Malaria
Exclusion Criteria
Metabolic Acidosis
Time frame: 48 hours
Acute renal failure
Time frame: By discharge
Acute pulmonary oedema
Time frame: By discharge
This study is completed, as verified in Jan 2010. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Oxford